Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 9/20 | 0.53 |
| ▸ | RXRB | P28702 | 9/20 | 0.53 |
| ▸ | RXRG | P48443 | 7/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30767774 | 0.88 | RXRA (0.56) | RXRARXRBRXRGPTGS1ABCC4 | |
| SCHEMBL10228775 | 0.86 | ABCC4 (0.69) | RXRARXRBRXRGPTGS1ABCC4 | |
| SCHEMBL23296113 | 0.84 | GRIN2D (0.57) | PTGS1ABCC4LMNAGAATSHR | |
| SCHEMBL12126599 | 0.81 | LMNA (0.75) | RXRARXRBRXRGPTGS1ABCC4 | |
| SCHEMBL491352 | 0.81 | RXRA (0.55) | RXRARXRBRXRGPTGS1ABCC4 | |
| SCHEMBL491539 | 0.81 | ABCC4 (0.52) | RXRARXRBRXRGPTGS1ABCC4 | |
| SCHEMBL491853 | 0.80 | PTGS1 (0.58) | RXRARXRBRXRGPTGS1ALDH1A1 | |
| SCHEMBL3575842 | 0.80 | FFAR1 (0.55) | RXRARXRBRXRGMEN1KMT2A | |
| SCHEMBL2525145 | 0.79 | CA2 (0.62) | PTGS1ABCC4LMNAGAATSHR | |
| SCHEMBL92022 | 0.79 | CA2 (0.62) | PTGS1ABCC4LMNAGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2016039-B1 | TERPHENYL DERIVATIVES FOR TREATMENT OF ALZHEIMER' S DISEASE | ORTHO MCNEIL JANSSEN PHARM (US) | 2012-08-01 | — | — | EP | claimed |
| US-8106236-B2 | Triaryl compounds and derivates thereof | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-01-31 | — | — | US | claimed |
| EP-1847524-B1 | Terphenyl derivatives for treatment of Alzheimer's disease | CELLZOME LTD (GB) | 2009-10-14 | — | — | EP | claimed |
| US-20070254957-A1 | TRIARYL COMPOUNDS AND DERIVATES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2007-11-01 | — | — | US | claimed |
| EP-1847524-A1 | Terphenyl derivatives for treatment of Alzheimer's disease | Cellzome (UK) Ltd. (GB) | 2007-10-24 | — | — | EP | claimed |
| US-8106236-B2 | Triaryl compounds and derivates thereof | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20070254957-A1 | TRIARYL COMPOUNDS AND DERIVATES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2007-11-01 | — | — | US | disclosed |
| EP-1847524-A1 | Terphenyl derivatives for treatment of Alzheimer's disease | Cellzome (UK) Ltd. (GB) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254957-A1 | TRIARYL COMPOUNDS AND DERIVATES THEREOF | BACE1, BACE2, APP | RXRA 1179/4885RXRB 1173/4885RXRG 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.